Baird analyst Wesley Golladay lowered the firm’s price target on Healthpeak Properties (DOC) to $24 from $25 and keeps an Outperform rating on the shares. The firm noted its Q4 results suggest the company is deploying capital om multiple fronts.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DOC:
- Potential Regulatory Changes Threaten Healthpeak Properties’ Investment in Healthcare Real Estate
- Healthpeak Properties: Strong Q4 Performance and Strategic Initiatives Justify Buy Rating
- Healthpeak Properties Reports Strong 2024 Results
- Healthpeak Properties Highlights Earnings Growth Amid Challenges
- Healthpeak Properties Reports Strong 2024 Financial Results